Johnson & Johnson was founded over 125 years ... worldwide leading brands such as Listerine oral care products and the Nicorette line of smoking cessation treatments. 2017 saw J&J make its biggest ...

Analysts cite Stelara exclusivity loss and MedTech competition as key challenges for Johnson & Johnson. Price target revisions: Tim Anderson lowers J&J forecast from $160 to $159. Get Wall Street ...

Gabby Jones / Bloomberg / Getty Images Johnson & Johnson is scheduled to report fourth-quarter earnings Wednesday morning, with analysts expecting sales and profits to grow year-over-year.

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments ...

Ratings for Johnson & Johnson (NYSE:JNJ) were provided by 12 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ...

Johnson & Johnson’s Consumer Health segment reported a revenue of $14.6 billion in the Full-Year 2021. It is projected that, following the separation, Kenvue will generate sales in over 100 ...

Johnson & Johnson is scheduled to report fourth-quarter earnings Wednesday morning, with analysts expecting sales and profits to grow year-over-year. The company's stock trended lower in the final ...

Pharmaceuticals and medical devices manufacturer Johnson & Johnson (NYSE:JNJ) reported fourth-quarter 2024 results on Wednesday, Jan. 22, that topped analyst consensus estimates. Revenue of $22.5 ...